Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: Results of the French prospective, observational EBIIA study

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 4, 2009, Pages 785-794

  Montravers, Philippe ^a   Lepape, Alain ^b   Dubreuil, Luc ^c   Gauzit, Rémy ^d   Pean, Yves ^e   Benchimol, Daniel ^f   Dupont, Hervé ^g  

^a BICHAT HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c UNIV LILLE   (France)

^d HÔTEL DIEU   (France)

^e INSTITUT MUTUALISTE MONTSOURIS   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Adequate antibiotic therapy; In vitro susceptibility; Peritonitis; Prognosis; Surgery

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; METRONIDAZOLE; OXACILLIN; PEFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TICARCILLIN; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; AGED; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; COMMUNICABLE DISEASE; COMORBIDITY; DISEASE SEVERITY; ENTEROBACTERIACEAE; FEMALE; FRANCE; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIAL IDENTIFICATION; MORTALITY; OBSERVATIONAL STUDY; PERITONITIS; PROGNOSIS; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; FEMALE; FRANCE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PERITONITIS; YOUNG ADULT;

EID: 62549100893     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp005     Document Type: Article

References (29)

1. Paterson DL, Rossi F, Baquero F et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005; 55: 965-73.
2. Rossi F, Baquero F, Hsueh PR et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006; 58: 205-10.
3. Baquero F, Hsueh PR, Paterson DL et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect (Larchmt) 2008 [Epub ahead of print].
4. Cattan P, Yin DD, Sarfati E et al. Cost of care for inpatients with community-acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis 2002; 21: 787-93.
5. Montravers P, Gauzit R, Muller C et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996; 23: 486-94.
6. Mosdell DM, Morris DM, Voltura A et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991; 214: 543-9.
7. Sturkenboom MC, Goettsch WG, Picelli G et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol 2005; 60: 438-43.
8. Antibiogram Committee of the French Society for Microbiology. CA-SFM; http://www.sfm.asso.fr (20 December 2008, date last accessed).
9. Garner JS, Jarvis WJ, Emori TG. CDC definitions for nosocomial infections. In: Olmsted R, ed. APIC Infection Control and Applied Epidemiology: Principles and Practice. St Louis: Mosby, 1996; 1-20.
10. Groupe REMIC de la SFM. REMIC - Référentiel en Microbiologie Médicale (Bactériologie et Mycologie Humaine), 2ème edition. Montmorency: 2M2, 2004.
11. Roehrborn A, Thomas L, Potreck O et al. The microbiology of postoperative peritonitis. Clin Infect Dis 2001; 33: 1513-9.
12. Sotto A, Lefrant JY, Fabbro-Peray P et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother 2002; 50: 569-76.
13. Seguin P, Laviolle B, Chanavaz C et al. Factors associated with multidrug-resistant bacteria in secondary peritonitis: Impact on antibiotic therapy. Clin Microbiol Infect 2006; 12: 980-5.
14. Montravers P, Dupont H, Gauzit R et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34: 646-52.
15. Dupont H, Carbon C, Carlet J et al. Monotherapy with a broad-spectrum β-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: A multicenter randomized controlled trial. Antimicrob Agents Chemother 2000; 44: 2028-33.
16. Montravers P, Chalfine A, Gauzit R et al. Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann Surg 2004; 239: 409-16.
17. Galas M, Decousser JW, Breton N et al. Nationwide study of the prevalence, characteristics, and molecular epidemiology of extended-spectrum-β-lactamase-producing Enterobacteriaceae in France. Antimicrob Agents Chemother 2008; 52: 786-9.
18. Rodriguez-Bano J, Alcala JC, Cisneros JM et al. Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168: 1897-902.
19. Sitges-Serra A, Lopez MJ, Girvent M et al. Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 2002; 89: 361-7.
20. Société Française d'Anesthésie et de Réanimation. Management of community-acquired peritonitis - consensus conference - short text. Ann Fr Anesth Reanim 2001; 20: 368s-73s.
21. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997-1005.
22. Burnett RJ, Haverstock DC, Dellinger EP et al. Definition of the role of enterococcus in intraabdominal infection: Analysis of a prospective randomized trial. Surgery 1995; 118: 716-21; discussion 21-3.
23. Christou NV, Turgeon P, Wassef R et al. Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group. Arch Surg 1996; 131: 1193-201.
24. Weigelt JA, Easley SM, Thal ER et al. Abdominal surgical wound infection is lowered with improved perioperative enterococcus and bacteroides therapy. J Trauma 1993; 34: 579-84; discussion 84-5.
25. Krobot K, Yin D, Zhang Q et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004; 23: 682-7.
26. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
27. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
28. Solomkin JS, Dellinger EP, Christou NV et al. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/ clindamycin for intra-abdominal infections. Ann Surg 1990; 212 581-91.
29. Cornaglia G, Hryniewicz W, Jarlier V et al. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect 2004; 10: 349-83.